ATLANTA, Nov. 3, 2011 /PRNewswire/ -- CryoLife,
Inc. (NYSE: CRY), a leading tissue processing and medical
device company focused on cardiac and vascular surgery, announced
today that Steven G. Anderson,
president and chief executive officer of CryoLife, Inc., is
scheduled to present in the upcoming Lazard Capital Markets Eighth
Annual Healthcare Conference on Tuesday,
November 15, 2011 at 3:00 pm
ET in New York City.
CryoLife is also scheduled to present at the Stephens, Inc Fall Investment Conference on
Wednesday, November 16, 2011.
Steven G. Anderson will present at 11:30 am ET in New York
City.
CryoLife's live presentations may be accessed through its Web
site, www.cryolife.com, on the Investor Relations page. An
archived copy of the presentations will be available for 90 days on
the same Web site.
About CryoLife
Founded in 1984, CryoLife, Inc. is a leader in the processing
and distribution of implantable living human tissues for use in
cardiac and vascular surgeries throughout the U.S. and Canada. CryoLife's CryoValve® SG
pulmonary heart valve, processed using CryoLife's proprietary
SynerGraft® technology, has FDA 510(k) clearance for the
replacement of diseased, damaged, malformed, or malfunctioning
native or prosthetic pulmonary valves. CryoLife's
CryoPatch® SG pulmonary cardiac patch has FDA 510(k)
clearance for the repair or reconstruction of the right ventricular
outflow tract (RVOT), which is a surgery commonly performed in
children with congenital heart defects, such as Tetralogy of
Fallot, Truncus Arteriosus, and Pulmonary Atresia. CryoPatch SG is
distributed in three anatomic configurations: pulmonary
hemi-artery, pulmonary trunk, and pulmonary branch.
CryoLife's BioGlue® Surgical Adhesive is FDA
approved as an adjunct to sutures and staples for use in adult
patients in open surgical repair of large vessels. BioGlue is
also CE marked in the European Community and approved in
Canada and Australia for use in soft tissue repair and
was recently approved in Japan for
use in the repair of aortic dissections. CryoLife, through
its subsidiary Cardiogenesis Corporation, specializes in the
treatment of cardiovascular disease and the sale of devices that
treat severe angina. Its market leading FDA-approved Holmium:
YAG laser system and single use fiber-optic delivery systems are
used to perform a surgical procedure known as Transmyocardial
Revascularization (TMR). CryoLife distributes
PerClot®, an absorbable powder hemostat, in the European
Community. CryoLife's BioFoam™ Surgical Matrix is
CE marked in the European Community for use as an adjunct in the
sealing of abdominal parenchymal tissues (liver and spleen) when
cessation of bleeding by ligature or other conventional methods is
ineffective or impractical.
For additional information about the company, visit CryoLife's
Web site: http://www.cryolife.com.
Contacts:
|
|
CryoLife
D. Ashley Lee
Executive Vice President, Chief
Financial Officer and Chief
Operating Officer
Phone: 770-419-3355
|
The Ruth Group
Nick Laudico / Zack
Kubow
646-536-7030 / 7020
nlaudico@theruthgroup.com
zkubow@theruthgroup.com
|
|
|
|
SOURCE CryoLife, Inc.